Gene editing in T cell therapy

Yongping Zhang; Wei Mu; Haoyi Wang

doi:10.1016/j.jgg.2017.09.002

Gene editing in T cell therapy

J Genet Genomics. 2017 Sep 20;44(9):415-422. doi: 10.1016/j.jgg.2017.09.002. Epub 2017 Sep 28.

Authors

Yongping Zhang¹, Wei Mu², Haoyi Wang³

Affiliations

¹ State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; Department of Hematology, Aerospace Center Hospital, Aerospace Clinical Medical College, Peking University, Beijing 100049, China.
² State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China.
³ State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: wanghaoyi@ioz.ac.cn.

PMID: 28967616
DOI: 10.1016/j.jgg.2017.09.002

Abstract

The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise. Gene editing holds tremendous potential for further improvements of T cell therapy. Here we review the applications of gene editing in various T cell therapies, focusing on antiviral strategies and cancer immunotherapies, and discuss the challenges and future prospects.

Keywords: CRISPR-Cas9; Gene editing; T cells.

Publication types

Review

MeSH terms

Adoptive Transfer
Animals
Cell- and Tissue-Based Therapy / methods*
Gene Editing / methods*
HIV Infections / genetics
HIV Infections / immunology
HIV Infections / therapy
Humans
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / therapy
T-Lymphocytes / cytology
T-Lymphocytes / immunology
T-Lymphocytes / metabolism*